1. Home
  2. PSTL vs MNPR Comparison

PSTL vs MNPR Comparison

Compare PSTL & MNPR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Postal Realty Trust Inc.

PSTL

Postal Realty Trust Inc.

HOLD

Current Price

$23.16

Market Cap

625.7M

Sector

Real Estate

ML Signal

HOLD

Logo Monopar Therapeutics Inc.

MNPR

Monopar Therapeutics Inc.

HOLD

Current Price

$110.15

Market Cap

587.4M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
PSTL
MNPR
Founded
N/A
2014
Country
United States
United States
Employees
N/A
N/A
Industry
Real Estate Investment Trusts
Biotechnology: Pharmaceutical Preparations
Sector
Real Estate
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
625.7M
587.4M
IPO Year
2018
2019

Fundamental Metrics

Financial Performance
Metric
PSTL
MNPR
Price
$23.16
$110.15
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
4
11
Target Price
$20.19
$107.00
AVG Volume (30 Days)
252.1K
274.6K
Earning Date
05-05-2026
05-08-2026
Dividend Yield
4.62%
N/A
EPS Growth
123.81
54.99
EPS
0.26
N/A
Revenue
$95,823,000.00
N/A
Revenue This Year
$18.01
N/A
Revenue Next Year
$11.38
N/A
P/E Ratio
$89.23
N/A
Revenue Growth
25.47
N/A
52 Week Low
$14.25
$29.18
52 Week High
$25.22
$124.82

Technical Indicators

Market Signals
Indicator
PSTL
MNPR
Relative Strength Index (RSI) 47.02 52.76
Support Level $22.12 $102.88
Resistance Level $24.28 $114.60
Average True Range (ATR) 0.69 6.69
MACD -0.04 -1.43
Stochastic Oscillator 50.24 26.91

Price Performance

Historical Comparison
PSTL
MNPR

About PSTL Postal Realty Trust Inc.

Postal Realty Trust Inc is an internally managed real estate investment trust. It is engaged in acquiring and managing properties mainly leased to the United States Postal Service, or the USPS, ranging from last-mile post offices to industrial facilities. The Trust's objective is to create stockholder value by generating risk-adjusted returns through expanding its portfolio of owned and managed postal properties leased to the USPS. The majority of its revenue is generated in the form of rental income.

About MNPR Monopar Therapeutics Inc.

Monopar Therapeutics Inc is a clinical-stage biopharmaceutical company developing a treatment for Wilson disease and novel radiopharmaceuticals for oncology. Its Wilson disease product candidate is ALXN1840, a late-stage, investigational once-daily, oral medicine. The group radiopharmaceutical programs consist of Phase 1-stage MNPR-101-Zr for imaging cancers, and Phase 1a-stage MNPR-101-Lu and late preclinical-stage MNPR-101-Ac for the treatment of cancers that express urokinase plasminogen activator receptor (uPAR). It build drug development pipeline through both in-house efforts and licensing of late preclinical- and clinical-stage therapeutics. The Company operates as a single reportable segment, focusing on the development of clinical and preclinical product candidates.

Share on Social Networks: